N Myles1,2, H Myles3,4, S Xia5, M Large5,6, S Kisely2,7, C Galletly4,8,9, R Bird10,11, D Siskind2,12. 1. Haematology Directorate, SA Pathology, Adelaide, SA, Australia. 2. School of Medicine, University of Queensland, St Lucia, Qld, Australia. 3. Country Health, Glenside, SA, Australia. 4. Discipline of Psychiatry, University of Adelaide, Adelaide, SA, Australia. 5. Prince of Wales Hospital, Randwick, NSW, Australia. 6. School of Psychiatry, University of New South Wales, Randwick, NSW, Australia. 7. Departments of Psychiatry, Community Health and Epidemiology, Dalhousie University, Halifax, NS, Canada. 8. Northern Adelaide Local Health Network, Adelaide, SA, Australia. 9. Mental Health, Ramsey Healthcare, Gilberton, SA, Australia. 10. Division of Cancer Services, Princess Alexandra Hospital, Woolloongabba, Qld, Australia. 11. School of Medicine, Griffith University, Parkwood, Qld, Australia. 12. Metro South Addiction and Mental Health Service, Woolloongabba, Qld, Australia.
Abstract
BACKGROUND: Clozapine is associated with life-threatening neutropenia. There are no previous meta-analyses of the epidemiology of clozapine-associated neutropenia. OBJECTIVES: To determine the cumulative incidence of mild, moderate and severe neutropenia, incidence of death related to severe neutropenia, case fatality rate of neutropenia and the longitudinal incidence of neutropenia following exposure to clozapine. DATA SOURCES: A systematic search of Medline, EMBASE and PsycINFO using search terms [clozapine OR clopine OR zaponex OR clozaril] AND [neutropenia OR agranulocytosis]. METHODS: Random effects meta-analysis to determine event rates and longitudinal incidence of events per 100 person-years of exposure. RESULTS: A total of 108 studies were included. The incidence of clozapine-associated neutropenia was 3.8% (95% CI: 2.7-5.2%) and severe neutropenia 0.9% (95% CI: 0.7-1.1%). The incidence of death related to neutropenia following prescription of clozapine was 0.013% (95% CI: 0.01-0.017%). The case fatality rate of severe neutropenia was 2.1% (95% CI: 1.6-2.8%). The peak incidence of severe neutropenia occurred at one month of exposure and declined to negligible levels after one year of treatment. CONCLUSION: Severe neutropenia associated with clozapine is a rare event and occurs early with a substantial decline in risk after one year of exposure. Death from clozapine-associated neutropenia is extremely rare. Implications for haematological monitoring are discussed.
BACKGROUND:Clozapine is associated with life-threatening neutropenia. There are no previous meta-analyses of the epidemiology of clozapine-associated neutropenia. OBJECTIVES: To determine the cumulative incidence of mild, moderate and severe neutropenia, incidence of death related to severe neutropenia, case fatality rate of neutropenia and the longitudinal incidence of neutropenia following exposure to clozapine. DATA SOURCES: A systematic search of Medline, EMBASE and PsycINFO using search terms [clozapine OR clopine OR zaponex OR clozaril] AND [neutropenia OR agranulocytosis]. METHODS: Random effects meta-analysis to determine event rates and longitudinal incidence of events per 100 person-years of exposure. RESULTS: A total of 108 studies were included. The incidence of clozapine-associated neutropenia was 3.8% (95% CI: 2.7-5.2%) and severe neutropenia 0.9% (95% CI: 0.7-1.1%). The incidence of death related to neutropenia following prescription of clozapine was 0.013% (95% CI: 0.01-0.017%). The case fatality rate of severe neutropenia was 2.1% (95% CI: 1.6-2.8%). The peak incidence of severe neutropenia occurred at one month of exposure and declined to negligible levels after one year of treatment. CONCLUSION: Severe neutropenia associated with clozapine is a rare event and occurs early with a substantial decline in risk after one year of exposure. Death from clozapine-associated neutropenia is extremely rare. Implications for haematological monitoring are discussed.
Authors: Madeleine S A Tan; Faraz Honarparvar; James R Falconer; Harendra S Parekh; Preeti Pandey; Dan J Siskind Journal: Psychopharmacology (Berl) Date: 2021-01-07 Impact factor: 4.530
Authors: C U Correll; Ofer Agid; Benedicto Crespo-Facorro; Andrea de Bartolomeis; Andrea Fagiolini; Niko Seppälä; Oliver D Howes Journal: CNS Drugs Date: 2022-06-27 Impact factor: 6.497
Authors: Bettina Konte; James T R Walters; Dan Rujescu; Sophie E Legge; Antonio F Pardiñas; Dan Cohen; Munir Pirmohamed; Jari Tiihonen; Annette M Hartmann; Jan P Bogers; Jan van der Weide; Karen van der Weide; Anu Putkonen; Eila Repo-Tiihonen; Tero Hallikainen; Ed Silva; Oddur Ingimarsson; Engilbert Sigurdsson; James L Kennedy; Patrick F Sullivan; Marcella Rietschel; Gerome Breen; Hreinn Stefansson; Kari Stefansson; David A Collier; Michael C O'Donovan; Ina Giegling Journal: Transl Psychiatry Date: 2021-04-12 Impact factor: 6.222
Authors: Isabella R Willcocks; Sophie E Legge; Mariana Nalmpanti; Lucy Mazzeo; Adrian King; John Jansen; Marinka Helthuis; Michael J Owen; Michael C O'Donovan; James T R Walters; Antonio F Pardiñas Journal: Front Pharmacol Date: 2021-04-16 Impact factor: 5.810
Authors: Dan Siskind; William G Honer; Scott Clark; Christoph U Correll; Alkomiet Hasan; Oliver Howes; John M Kane; Deanna L Kelly; Robert Laitman; Jimmy Lee; James H MacCabe; Nick Myles; Jimmi Nielsen; Peter F Schulte; David Taylor; Helene Verdoux; Amanda Wheeler; Oliver Freudenreich Journal: J Psychiatry Neurosci Date: 2020-05-01 Impact factor: 6.186
Authors: Daniela Fonseca de Freitas; India Patel; Giouliana Kadra-Scalzo; Megan Pritchard; Hitesh Shetty; Matthew Broadbent; Rashmi Patel; Johnny Downs; Aviv Segev; Mizanur Khondoker; James H MacCabe; Kamaldeep Bhui; Richard D Hayes Journal: Soc Psychiatry Psychiatr Epidemiol Date: 2022-03-04 Impact factor: 4.519